Treats major depressive disorder (MDD). ANDA 215113, held by Msn. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 215113 (Doxepin Hydrochloride), held by Msn, was first approved by FDA on Jun 24, 2022, with 0 approved supplements and 0 published complete response letters.
Doxepin Hydrochloride capsules are indicated for the treatment of major depressive disorder (MDD) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 24, 2022 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 10MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 25MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 50MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 75MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 100MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters